Akers Biosciences starts asthma assay trials
This article was originally published in Clinica
Executive Summary
Akers Biosciences has begun clinical trials of its rapid point-of-care test for asthma in around 200 patients. The disposable Breath Asthma Check assay measures the acidity of exhaled breath condensate; this indicates airway acidity, which is associated with airway inflammation. The test could provide an inexpensive, rapid screening aid in the diagnosis of early-stage asthma, and may also be used as a compliance tool for physicians to ensure successful drug therapy regimens. Thorofare, New Jersey-based Akers will use the trial results to submit regulatory approval applications for the test in the US and EU. This is scheduled for the third quarter of 2011.